MedTrace Logo

Evaluation of the Sevoflurane Consumption During General Anesthesia When Using the MemsorbTM Membrane

NCT04539405 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-01-23

No results posted yet for this study

Summary

The study aims at determining whether replacing the classical chemical absorber Dräegersorb 800+ on Dräeger Perseus A500 machines (Dräeger, Lübeck, Germany) by the new membrane technology-based product (Memsorb™, DMF Medical Inc., Halifax, NS, Canada) with the help of high-quality monitoring (BIS and NOL) and high-end ventilators (Dräeger Perseus A500 machines; Dräeger, Lübeck, Germany) that allow minimal fresh gas flow, will significantly decrease the use of sevoflurane and its related atmospheric pollution.

Conditions

  • Laparoscopic General, Gynecological and Urologic Surgeries

Interventions

DEVICE

To evaluate sevoflurane consumption when using Memsorb

Sevoflurane administration at 0.2L.min-1 (minimal gas flow)

DEVICE

To evaluate sevoflurane consumption when using classical Dräegersorb

Sevoflurane administration at 2L.min-1 (classical gas flow)

Sponsors & Collaborators

  • DMF Medical Incorporated

    collaborator INDUSTRY

  • Ciusss de L'Est de l'Île de Montréal

    lead OTHER

Principal Investigators

  • Philippe PR Richebe, MD, PhD · CIUSSS Est de l'île de Montréal

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2022-02-18
Completion
2022-02-18

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539405 on ClinicalTrials.gov